HealthCare Royalty Partners Promotes Matthew Reber to Managing Director

Jun 27, 2013, 10:00 ET from HealthCare Royalty Partners

STAMFORD, Conn., June 27, 2013 /PRNewswire/ -- HealthCare Royalty Partners ("HC Royalty"), a global healthcare investment firm, today announced that Matthew Q. Reber has been promoted to Managing Director. Mr. Reber joined the firm in 2008 and previously served as a Principal. In his expanded role, Mr. Reber will continue to source and execute royalty transactions as well as support the Founding Managing Directors in the overall management of the portfolio. Over the course of his career, he has worked on more than $500 million in royalty financings, including an investment of up to $70 million in TearScience and a $50 million investment in Raptor Pharmaceuticals. He has over a decade of healthcare investing experience, and first began working with the founders in 2004.  Previously, Mr. Reber worked at Paul Capital Partners, Oak Hill Capital Partners, J.H. Whitney and Morgan Stanley.

"Matt has demonstrated exceptional senior leadership over the past five years and we are honored to make him the firm's first investment professional promoted to Managing Director. He is a forward thinker and a strategic investor and will continue to be a tremendous asset to the team as we enter our next phase of growth," commented Todd Davis, Founding Managing Director at HC Royalty.

The investment team at HC Royalty has grown to 10 professionals over the past six years under the leadership of Greg Brown, Todd Davis and Clarke Futch. This team has invested in 34 pharmaceutical and medical device products through two HC Royalty investment funds including LYRICA®, Oracea®, Cetrotide®, and PROCYSBI™, an orphan drug recently approved by the FDA for the treatment of nephropathic cystinosis.

About HealthCare Royalty Partners
HealthCare Royalty Partners is a global healthcare investment firm that provides financing solutions to healthcare companies and royalty owners with interests in approved pharmaceutical and medical device products. The firm's senior investment team has participated in 45 royalty financings valued at over $2 billion over the past decade. For more information, visit  

Synthetic Royalty® is a registered trademark of HealthCare Royalty Management, LLC.

Media Contact:          
Kellie Walsh

SOURCE HealthCare Royalty Partners